云南贝泰妮生物科技集团股份有限公司2025年年度报告摘要-英文版

Yunnan Botanee Bio-Technology Group Co., Ltd.Summary of the 2025 Annual Report1Stock code: 300957Stock abbreviation: BotaneeAnnouncement number: 2026-011Yunnan Botanee Bio-Technology Group Co., Ltd.Summary of the 2025 Annual ReportI. Important Notice(1) This annual report summary is derived from the full text of the annual report. To fullyunderstand the Company’s operating results, financial status, and future development plans,investors should carefully read the full annual report on the media designated by the ChinaSecurities Regulatory Commission.(2) All directors attended the Board meeting for deliberating on this report.(3) Tianheng Certified Public Accountants (Special General Partnership) issued a standardunqualified opinion on the Company’s financial report for the year.Notice of the non-standard audit opinion□ Applicable Not applicableThe Company was not profitable at the time of its listing and has not achieved profitability to date□ Applicable Not applicableProfit distribution plan or capital reserve transfer plan to increase capital approved by the boardduring the reporting periodApplicable □ Not applicableThe profit distribution plan approved by the Board during this meeting is: Based on the Company’stotal share capital of 423,600,000 shares, subtracting 2,307,118 shares in the repurchase specialaccount that do not participate in the profit distribution, i.e., using 421,292,882 shares as the base, acash dividend of CNY3.50 (tax included) will be distributed for every 10 shares to all shareholders,with 0 bonus share (tax included) and 0 share for every 10 shares transferred to all shareholdersfrom capital reserve.The profit distribution plan for preferred shares approved by the Board during the reporting period□ Applicable Not applicableII. Company Overview1. Company ProfileStock nameBotaneeStock code300957Stock listing exchangeShenzhen Stock ExchangeContact person and contact informationBoard SecretarySecurities representativeNameWang LongXu MinjingOffice addressNo. 53, Keyi Road, Kunming High-techIndustrial Development Zone, Kunming,No. 53, Keyi Road, Kunming High-techIndustrial Development Zone, Kunming,Yunnan Botanee Bio-Technology Group Co., Ltd.Summary of the 2025 Annual Report2Yunnan ProvinceYunnan ProvinceFax021-6232 1125021-6232 1125Tel.021-6232 1125021-6232 1125Emailir@botanee.comir@botanee.com2. Overview of Main Business or Products During the Reporting Period2.1 Company’s Main Business and ProductsYunnan Botanee Bio-Technology Group Co., Ltd. (hereinafter referred to as the “Company”)focuses on the development of multiple brands, including core brand Winona as well as WinonaBaby, AOXMED, Beforteen, Za, PURE&MILD and TriPollar1. We specialize in providingprofessional and effective skincare products using pure natural plant-derived active ingredients,with a particular emphasis on sensitive skin. As a specialized cosmetics manufacturer that integratesdeeply with internet- based sales channels, our mission is to “create Ch

立即下载
综合
2026-04-27
15页
0.69M
收藏
分享

云南贝泰妮生物科技集团股份有限公司2025年年度报告摘要-英文版,点击即可下载。报告格式为PDF,大小0.69M,页数15页,欢迎下载。

本报告共15页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共15页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
2020-2026Q1 财通证券收入结构
综合
2026-04-27
来源:2025年年报及2026年一季报点评:自营业务弹性释放,26Q1归母净利润翻倍高增
查看原文
2020-2026Q1 财通证券 ROE 图4:2020-2026Q1 财通证券杠杆率
综合
2026-04-27
来源:2025年年报及2026年一季报点评:自营业务弹性释放,26Q1归母净利润翻倍高增
查看原文
2020-2026Q1 财通证券营收 图2:2020-2026Q1 财通证券归母净利润
综合
2026-04-27
来源:2025年年报及2026年一季报点评:自营业务弹性释放,26Q1归母净利润翻倍高增
查看原文
图 36中国外周动脉疾病患病人数预测,2019-2035E
综合
2026-04-27
来源:2025年年度报告
查看原文
图 352014-2024 年心脏外科体外循环模式下的总手术量(单位:万例)
综合
2026-04-27
来源:2025年年度报告
查看原文
图 342019 年-2030 年 E 中国血液透析市场规模及预测
综合
2026-04-27
来源:2025年年度报告
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起